DekaBank Deutsche Girozentrale Sells 5,311 Shares of Humana Inc. (NYSE:HUM)

DekaBank Deutsche Girozentrale cut its stake in shares of Humana Inc. (NYSE:HUM) by 9.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 51,840 shares of the insurance provider’s stock after selling 5,311 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Humana were worth $18,725,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. SP Asset Management LLC raised its holdings in shares of Humana by 75.0% in the second quarter. SP Asset Management LLC now owns 1,171 shares of the insurance provider’s stock valued at $437,000 after buying an additional 502 shares during the last quarter. AGF Management Ltd. raised its holdings in shares of Humana by 17.7% in the second quarter. AGF Management Ltd. now owns 7,382 shares of the insurance provider’s stock valued at $2,758,000 after buying an additional 1,111 shares during the last quarter. Kinsale Capital Group Inc. raised its holdings in shares of Humana by 29.8% in the second quarter. Kinsale Capital Group Inc. now owns 9,715 shares of the insurance provider’s stock valued at $3,630,000 after buying an additional 2,231 shares during the last quarter. Coldstream Capital Management Inc. raised its holdings in shares of Humana by 52.7% in the second quarter. Coldstream Capital Management Inc. now owns 2,606 shares of the insurance provider’s stock valued at $974,000 after buying an additional 899 shares during the last quarter. Finally, Gryphon Financial Partners LLC bought a new position in shares of Humana in the second quarter valued at about $625,000. 92.38% of the stock is owned by institutional investors.

Humana Price Performance

Shares of HUM opened at $321.56 on Monday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.66 and a current ratio of 1.66. The stock has a 50 day simple moving average of $364.11 and a 200 day simple moving average of $346.85. Humana Inc. has a 52-week low of $298.61 and a 52-week high of $530.54. The firm has a market capitalization of $38.72 billion, a PE ratio of 20.02, a P/E/G ratio of 2.56 and a beta of 0.50.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.89 by $1.07. Humana had a return on equity of 16.12% and a net margin of 1.53%. The business had revenue of $29.54 billion during the quarter, compared to analyst estimates of $28.52 billion. During the same period in the previous year, the firm earned $8.94 EPS. Humana’s quarterly revenue was up 10.4% compared to the same quarter last year. Sell-side analysts predict that Humana Inc. will post 16 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Monday, September 30th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.10%. The ex-dividend date is Monday, September 30th. Humana’s dividend payout ratio (DPR) is currently 22.04%.

Analysts Set New Price Targets

A number of research analysts recently issued reports on HUM shares. Morgan Stanley started coverage on Humana in a report on Monday, June 24th. They issued an “equal weight” rating and a $374.00 price target for the company. JPMorgan Chase & Co. boosted their price objective on Humana from $332.00 to $396.00 and gave the stock a “neutral” rating in a report on Wednesday, August 21st. Royal Bank of Canada boosted their price objective on Humana from $385.00 to $400.00 and gave the stock an “outperform” rating in a report on Thursday, September 5th. Robert W. Baird began coverage on Humana in a report on Thursday, May 30th. They set a “neutral” rating and a $374.00 price objective for the company. Finally, Oppenheimer boosted their price objective on Humana from $370.00 to $400.00 and gave the stock an “outperform” rating in a report on Thursday, August 1st. Thirteen analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $398.70.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.